Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
1276
mi
from 02139
Omaha, NE
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
1276
mi
from 02139
Omaha, NE
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
194
mi
from 02139
Newark, NJ
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
194
mi
from 02139
Newark, NJ
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
180
mi
from 02139
New York, NY
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
180
mi
from 02139
New York, NY
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
547
mi
from 02139
Cleveland, OH
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
547
mi
from 02139
Cleveland, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
1393
mi
from 02139
Tulsa, OK
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
1393
mi
from 02139
Tulsa, OK
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
2530
mi
from 02139
Portland, OR
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
2530
mi
from 02139
Portland, OR
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
268
mi
from 02139
Philadelphia, PA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
915
mi
from 02139
Chattanooga, TN
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
915
mi
from 02139
Chattanooga, TN
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated:  4/19/2012
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha �Agent(s)
Status: Enrolling
Updated: 4/19/2012
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated:  5/11/2012
Clinical Research Facility
1338
mi
from 02139
Fort Smith, AR
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated: 5/11/2012
Clinical Research Facility
1338
mi
from 02139
Fort Smith, AR
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated:  5/11/2012
Clinical Research Facility
2678
mi
from 02139
Santa Clara, CA
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated: 5/11/2012
Clinical Research Facility
2678
mi
from 02139
Santa Clara, CA
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated:  5/11/2012
Clinical Research Facility
643
mi
from 02139
Ann Arbor, MI
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated: 5/11/2012
Clinical Research Facility
643
mi
from 02139
Ann Arbor, MI
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated:  5/11/2012
Clinical Research Facility
1079
mi
from 02139
Rochester, MN
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated: 5/11/2012
Clinical Research Facility
1079
mi
from 02139
Rochester, MN
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated:  5/11/2012
Clinical Research Facility
547
mi
from 02139
Cleveland, OH
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated: 5/11/2012
Clinical Research Facility
547
mi
from 02139
Cleveland, OH
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated:  5/11/2012
Clinical Research Facility
2530
mi
from 02139
Portland, OR
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated: 5/11/2012
Clinical Research Facility
2530
mi
from 02139
Portland, OR
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated:  5/11/2012
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated: 5/11/2012
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated:  5/11/2012
Clinical Research Facility
2091
mi
from 02139
Salt Lake City, UT
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Status: Enrolling
Updated: 5/11/2012
Clinical Research Facility
2091
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis
A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis
Status: Enrolling
Updated:  7/17/2012
Clinical Science Institute
2600
mi
from 02139
Santa Monica, CA
A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis
A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis
Status: Enrolling
Updated: 7/17/2012
Clinical Science Institute
2600
mi
from 02139
Santa Monica, CA
Click here to add this to my saved trials
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated:  8/20/2012
Dow Clinical Study Site
2687
mi
from 02139
Santa Rosa, CA
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated: 8/20/2012
Dow Clinical Study Site
2687
mi
from 02139
Santa Rosa, CA
Click here to add this to my saved trials
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated:  8/20/2012
Dow Clinical Study Site
601
mi
from 02139
Clinton Township, MI
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated: 8/20/2012
Dow Clinical Study Site
601
mi
from 02139
Clinton Township, MI
Click here to add this to my saved trials
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated:  8/20/2012
Dow Cliincal Study Site
579
mi
from 02139
Fort Gratiot, MI
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated: 8/20/2012
Dow Cliincal Study Site
579
mi
from 02139
Fort Gratiot, MI
Click here to add this to my saved trials
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated:  8/20/2012
Dow Clinical Study Site
939
mi
from 02139
Nashville, TN
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated: 8/20/2012
Dow Clinical Study Site
939
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated:  8/20/2012
Dow Clinical Study Site
1691
mi
from 02139
Austin, TX
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated: 8/20/2012
Dow Clinical Study Site
1691
mi
from 02139
Austin, TX
Click here to add this to my saved trials
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated:  8/20/2012
Dow Clinical Study Site
470
mi
from 02139
Norfolk, VA
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Status: Enrolling
Updated: 8/20/2012
Dow Clinical Study Site
470
mi
from 02139
Norfolk, VA
Click here to add this to my saved trials
Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Status: Enrolling
Updated:  9/26/2012
Univ of Rochester Medical Center
335
mi
from 02139
Rochester, NY
Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Status: Enrolling
Updated: 9/26/2012
Univ of Rochester Medical Center
335
mi
from 02139
Rochester, NY
Click here to add this to my saved trials
Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis
A Single-Center, Open-Label Study to Assess the Effects of the Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis Evaluated With the PASI, PGA and DLQI
Status: Enrolling
Updated:  10/9/2012
Wayne State University Physician Group Dermatology
616
mi
from 02139
Dearborn, MI
Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis
A Single-Center, Open-Label Study to Assess the Effects of the Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis Evaluated With the PASI, PGA and DLQI
Status: Enrolling
Updated: 10/9/2012
Wayne State University Physician Group Dermatology
616
mi
from 02139
Dearborn, MI
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
2588
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
1256
mi
from 02139
Miami, FL
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
1256
mi
from 02139
Miami, FL
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
882
mi
from 02139
Athens, GA
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
882
mi
from 02139
Athens, GA
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
847
mi
from 02139
Chicago, IL
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
847
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
730
mi
from 02139
Hazard, KY
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
730
mi
from 02139
Hazard, KY
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
2
mi
from 02139
Boston, MA
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
2
mi
from 02139
Boston, MA
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
219
mi
from 02139
Bridgewater, NJ
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
219
mi
from 02139
Bridgewater, NJ
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
1915
mi
from 02139
Santa Fe, NM
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
1915
mi
from 02139
Santa Fe, NM
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
189
mi
from 02139
Brooklyn, NY
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
189
mi
from 02139
Brooklyn, NY
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
616
mi
from 02139
Chapel Hill, NC
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
616
mi
from 02139
Chapel Hill, NC
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
268
mi
from 02139
Philadelphia, PA
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
1574
mi
from 02139
Fort Worth, TX
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
1574
mi
from 02139
Fort Worth, TX
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
2093
mi
from 02139
American Fork, UT
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
2093
mi
from 02139
American Fork, UT
Click here to add this to my saved trials
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
2481
mi
from 02139
Seattle, WA
A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
2481
mi
from 02139
Seattle, WA
Click here to add this to my saved trials
Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis
Effect of Topical Application of Sulforaphane- Containing Broccoli Sprout Extracts on Radiation Dermatitis During External-beam Radiation Therapy for Breast Cancer
Status: Enrolling
Updated:  11/15/2012
Johns Hopkins University
356
mi
from 02139
Baltimore, MD
Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis
Effect of Topical Application of Sulforaphane- Containing Broccoli Sprout Extracts on Radiation Dermatitis During External-beam Radiation Therapy for Breast Cancer
Status: Enrolling
Updated: 11/15/2012
Johns Hopkins University
356
mi
from 02139
Baltimore, MD
Click here to add this to my saved trials
A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
A Randomized, Investigator-Blinded Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
Status: Enrolling
Updated:  1/28/2013
Yale University
118
mi
from 02139
New Haven, CT
A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
A Randomized, Investigator-Blinded Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
Status: Enrolling
Updated: 1/28/2013
Yale University
118
mi
from 02139
New Haven, CT
Click here to add this to my saved trials
Improving Psoriasis Through Health and Well-Being
Improving Psoriasis Through Health and Well-Being
Status: Enrolling
Updated:  1/31/2013
University of Rochester; University Dermatology Associates
335
mi
from 02139
Rochester, NY
Improving Psoriasis Through Health and Well-Being
Improving Psoriasis Through Health and Well-Being
Status: Enrolling
Updated: 1/31/2013
University of Rochester; University Dermatology Associates
335
mi
from 02139
Rochester, NY
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  2/26/2013
Clinical Research Facility
1048
mi
from 02139
Birmingham, AL
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 2/26/2013
Clinical Research Facility
1048
mi
from 02139
Birmingham, AL
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  2/26/2013
Clinical Research Facility
2362
mi
from 02139
Henderson, NV
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 2/26/2013
Clinical Research Facility
2362
mi
from 02139
Henderson, NV
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  2/26/2013
Clinical Research Facility
2491
mi
from 02139
Bend, OR
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 2/26/2013
Clinical Research Facility
2491
mi
from 02139
Bend, OR
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  2/26/2013
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 2/26/2013
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  2/26/2013
Clinical Research Facility
1601
mi
from 02139
Houston, TX
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 2/26/2013
Clinical Research Facility
1601
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated:  2/26/2013
Clinical Research Facility
2091
mi
from 02139
Salt Lake City, UT
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis
Status: Enrolling
Updated: 2/26/2013
Clinical Research Facility
2091
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis
A Randomized Open-label Two-arm Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Protocol: Psoriasis IIT
Status: Enrolling
Updated:  4/17/2013
Icahn School of Medicine at Mount Sinai
mi
from 02139
New York, NY
Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis
A Randomized Open-label Two-arm Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Protocol: Psoriasis IIT
Status: Enrolling
Updated: 4/17/2013
Icahn School of Medicine at Mount Sinai
mi
from 02139
New York, NY
Click here to add this to my saved trials